Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership—Schizophrenia

作者：Henry R. Cowan, Danielle Pratt, Jai L Shah, Scott W Woods, Luis Alameda, Martin Lepage, Stewart A. Shankman, Jean Addington, C Martinez Arango, Carrie E Bearden, Sylvain Bouix, Nicholas J Breitborde, Matthew R Broome, Kristin S Cadenhead, Monica E. Calkins, Rolando I Castillo-Passi, Eric Chen, Jimmy Choi, Philippe Conus, Cheryl M Corcoran, Barbara A Cornblatt, Covadonga M Diaz-Caneja, Lauren M. Ellman, Paolo Fusar-Poli, Pablo A Gaspar, Carla Gerber, Louise Birkedal Glenthøj, Cláudia Gonçalves, Leslie E. Horton, C HUI, Joseph Kambeitz, Lana Kambeitz-Ilankovic, René S. Kahn, John M Kane, Matcheri S Keshavan, Minah Kim, Sung-Wan Kim, Nikolaos Koutsouleris, Jun Soo Kwon, Kerstin Langbein, Daniel Mamah, Daniel H Mathalon, Patrick D McGorry, Barnaby Nelson, Merete Nordentoft, Ofer Pasternak, Godfrey D Pearlson, J Perez, Diana O Perkins, Albert R Powers, Jack Rogers, Fred W Sabb, Jason Schiffman, Martha E Shenton, Steven M Silverstein, Stefan Smesny, William S Stone, Gregory P Strauss, Judy L. Thompson, Rachel Upthegrove, Swapna Verma, Yi-Xiang Wang, Daniel H Wolf, A. Yung, Tianhong Zhang, Courtney Crawford, Walid Yassin, Sinéad Kelly, Michael Coleman, Grace Jacobs, Kathryn E Lewandowski, Nora Penzel, Justin Baker, Guillermo Cecci, Kelly Allott, Kate Buccilli, Sophie Tod, Lauren Addamo, Lihua Xu, Accelerating Medicines Partnership®—Schizophrenia (AMP® SCZ), Vijay A Mittal · 发表于：Schizophrenia Bulletin · 年份：2025 · DOI：10.1093/schbul/sbaf197 · 被引用次数：2 · 研究领域：Schizophrenia research and treatment、Attention Deficit Hyperactivity Disorder、Bipolar Disorder and Treatment

BACKGROUND AND HYPOTHESES: Functional impairment often precedes attenuated psychotic symptoms (APS) in youth at clinical high risk (CHR) for psychosis. This impairment has been linked to baseline symptoms and cognition, but the roles of developmental stage of APS onset and comorbid depression/anxiety are not well understood. Accelerating Medicines Partnership-Schizophrenia's diverse international sample and broad symptom assessment facilitate a detailed analysis of premorbid functioning. STUDY DESIGN: Premorbid adjustment and baseline symptoms and cognition were examined in 1056 individuals at CHR (n = 482 early-symptom, n = 574 late-symptom [first CHR-level APS in childhood/early adolescence vs. late adolescence/adulthood]). In the late-symptom group, growth curve models tested adjustment trends from childhood through late adolescence. Incremental relationships between adjustment, symptoms, and cognition were tested controlling for depression/anxiety. STUDY RESULTS: Premorbid social maladjustment correlated with baseline negative symptoms (r ≥ .25, P < .001). Premorbid academic maladjustment correlated with baseline negative symptoms (r ≥ .17, P ≤ .007) and cognitive impairment (r ≥ .27, P ≤ .001). Effects did not differ between early- and late-symptom subgroups (Δr ≤ .12, z ≤ 2.00, P > .05). Social adjustment deteriorated over time in participants with more baseline negative symptoms (γ = 0.14, P < .001) or cognitive impairment (γ ≥ -0.01, P < .004), even when controlling f...